structural and functional outcomes in animal models of stroke: what do they measure? malcolm macleod...
TRANSCRIPT
![Page 1: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/1.jpg)
Structural and functional outcomes in animal models of stroke: What do they measure?
Malcolm MacleodUniversity of Edinburgh
![Page 2: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/2.jpg)
The problem …
• The failure of successful translation from animal studies to clinical trials
• Primary endpoint in animal studies is usually a structural outcome
• Primary endpoint in clinical trials is usually a functional outcome
• Is there a relationship, in animals, between structural and functional outcome?
![Page 3: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/3.jpg)
1026
1026 interventions in experimental stroke
![Page 4: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/4.jpg)
1026603
1026 interventions in experimental stroke
Tested in focal ischaemia
![Page 5: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/5.jpg)
1026883374
1026 interventions in experimental stroke
Effective in focal ischaemia
![Page 6: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/6.jpg)
1026883550
97 18
1026 interventions in experimental stroke
Tested in clinical trial
![Page 7: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/7.jpg)
1026883550
97 171 3
1026 interventions in experimental stroke
Effective in clinical trial
![Page 8: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/8.jpg)
Progress to date:
• Better understanding of the limited internal validity of animal studies
• Better understanding of publication bias
• Better understanding of the limited external validity of animal studies
![Page 9: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/9.jpg)
Methodological approach
• Written review protocol – hypothesis, inclusion and exclusion criteria, analyses prespecified
• Standardised search strategy – 3 online databases, conference abstracts, dual screening
• Data extraction to bespoke database/analysis tool
• Random effects weighted mean difference stratified meta-analysis or meta-regression
• Publication bias by Funnel plot, Egger regression, Trim and Fill
![Page 10: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/10.jpg)
CAMARADES
Disease model Interventions
Publications Experiments Animals
Focal cerebral ischaemia
17 556 1439 20690
Intracerebral Haemorrhage
62 97 407 3647
Experimental Allergic Encephalomyelitis
36 (1717) 123 (1152) 438 7224
Transgenic models of AD
207 612 1794 22000
Parkinson’s Disease
28 57 303 2245
Spinal Cord Injury
34 69 331 3596
Total 2543 4712 59402
![Page 11: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/11.jpg)
Internal validity
9 publications, 29 experiments, 408 animals 44% (35-53%) improvement in outcome
![Page 12: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/12.jpg)
Publication Bias
![Page 13: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/13.jpg)
External validity
NXY-059
“Normal”BPEffi
cacy
tPA
“Normal”BP
Effi
cacy
![Page 14: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/14.jpg)
External validity – good practice
![Page 15: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/15.jpg)
Surrogate outcomes and biomarkers
![Page 16: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/16.jpg)
Surrogate outcomes and biomarkers
Surrogate outcome
Functional outcome
![Page 17: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/17.jpg)
Can animal models help?
• In animal studies– Does structural outcome predict functional
outcome?– Does this relationship hold across interventions?
• Inclusion criteria: – Reports of the efficacy of a candidate stroke
drug in an animal model of focal cerebral ischaemia
– Structural and functional outcome reported from the same cohort of animals
– Simultaneous measurement of structural and functional outcome
![Page 18: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/18.jpg)
Data
1047
257
16
71
131
71
21
25
110
13
110
12
24
18
26
9
Experiments reporting any
outcome
299TOTAL
58Stem Cells
11Other Thrombolytics
20Nicotinamide
54Thrombolytics
16NOS Inhibitors
8FK506
0NOS Donors
42Hypothermia
4Melatonin
51Growth Factors
3NXY-059
7Enriched Environment
16Tirilazad
8Minocycline
1IL1-RA
Experiments reporting structural and
functional outcomesDrug Group
![Page 19: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/19.jpg)
Raw correlation
Raw correlation coefficient = 0.439
adjusted r2=0.301
∆ F
un
ctio
nal
ou
tco
me
∆ Structural outcome
Better
Better
Worse
![Page 20: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/20.jpg)
Structural Outcome
Coefficient 95% CI
Constant (tPA) 23.9 17.1-30.7
Other lytics 19.3 2.93-35.7
FK506 19.9 1.62-38.1
Tirilazad 21.4 7.91-34.9
Nicotinamide 23.4 6.75-40.2
Hypothermia 26.1 15.9-36.4
NXY 059 29.1 0.43-57.8
Delay to assessment (days) -0.01 -0.02-0.00
% improvement (SO) = 23.9 + f(drug) -0.01*(days to assessment)
Adjusted r2 = 0.24
![Page 21: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/21.jpg)
Functional Outcome
Coefficient 95% CI
Structural outcome (Infarct Volume) 0.47 0.37 to 0.56
Stem cells 10.0 1.9 to 18.1
Hypothermia 11.2 2.4 to 19.9
FK506 18.4 4.2 to 32.6
Minocycline 18.5 5.1 to 31.9
Nicotinamide 19.9 10.1 to 29.7
NOS Inhibitors 20.7 10.4 to 30.9
Tirilazad 22.9 8.1 to 37.9
Delay to assessment (days) 0.58 0.36 to 0.82
Delay to treatment (hours) -0.96 -1.44 to -0.48
% improvement (FO) = 0.47*SO + f(drug) + 0.58*(days to assessment) – 0.96*(hours to drug administration)
Adjusted r2 = 0.56
![Page 22: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/22.jpg)
Summary
Structural Outcome Functional Outcome Independent effects on both
tPA Stem cells FK506
Other lytics Minocycline Tirilazad
NXY 059 NOS Inhibition Nicotinamide
Hypothermia
Delay to treatment (-ve)Delay to assessment
(-ve SO, +ve FO)
Lesion Structural Outcome Functional Outcome
![Page 23: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/23.jpg)
Summary
Structural Outcome Functional Outcome Independent effects on both
tPA Stem cells FK506
Other lytics Minocycline Tirilazad
NXY 059 NOS Inhibition Nicotinamide
Hypothermia
Delay to treatment (-ve)Delay to assessment
(-ve SO, +ve FO)
Lesion Structural Outcome Functional Outcome
![Page 24: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/24.jpg)
Summary
Structural Outcome Functional Outcome Independent effects on both
tPA Stem cells FK506
Other lytics Minocycline Tirilazad
NXY 059 NOS Inhibition Nicotinamide
Hypothermia
Delay to treatment (-ve)Delay to assessment
(-ve SO, +ve FO)
Lesion Structural Outcome Functional Outcome
![Page 25: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/25.jpg)
Summary
Structural Outcome Functional Outcome Independent effects on both
tPA Stem cells FK506
Other lytics Minocycline Tirilazad
NXY 059 NOS Inhibition Nicotinamide
Hypothermia
Delay to treatment (-ve)Delay to assessment
(-ve SO, +ve FO)
Lesion Structural Outcome Functional Outcome
![Page 26: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/26.jpg)
DISCUSSION
• Structural outcome explains around 30% of the variation in functional outcome
• Crucially, this relationship is different for different interventions
• Surrogate outcome measures in Phase II are likely to be intervention specific rather than disease specific
• Nonetheless, this approach might help with rational selection of combination therapies
![Page 27: Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh](https://reader035.vdocuments.site/reader035/viewer/2022062417/5515126b550346a80c8b5c05/html5/thumbnails/27.jpg)
Acknowledgements
• CAMARADES collaborators– Bart van der Worp (Hypothermia)– Philip Bath (NOS Inhibitors)– Jen Lees/ David Howells/ Simon Koblar
(Stem cells)
• NHS Lothian R&D Infrastructure Funding
• Edinburgh MRC Trials Methodology Hub